Archives
-
Pexidartinib and the Next Era of Myeloid Oncology
2026-10-10
Pexidartinib (PLX3397) offers a pharmacologic lens on CSF1R biology, but its greatest translational value emerges when receptor inhibition is interpreted alongside macrophage state, SPP1 biology, spatial context, and evidence boundaries. This article connects CSF1R-mediated signaling inhibition with recent findings on SPP1-high tumor-associated macrophages while distinguishing direct evidence from forward-looking research strategy.
-
EZ Cap™ Reagent GG: p21 mRNA Evidence
2026-10-09
Explore how p21 mRNA–LNP delivery could support localized bladder cancer therapy, and where EZ Cap™ Reagent GG fits conceptually in mRNA cap-quality assessment. This evidence-led analysis separates published findings from product-specific claims and highlights translational limitations.
-
Stable-Isotope UHPLC–MS/MS for Methylated Purines
2026-10-09
Zhang, Zhang, and Wang reported a stable isotope-diluted UHPLC–ESI-MS/MS method for measuring 12 purine ribonucleosides, including 10 methylated species, in cultured-cell extracts. Enhanced ionization, chromatographic resolution of isomers, and matrix-aware cleanup improved sensitivity and enabled quantification of low-abundance RNA-derived nucleosides, while the study also defines important limits for biological interpretation.
-
Bestatin and Actinonin: Evidence for Intracellular Action
2026-10-08
Grujic and Renko compared the antiproliferative effects of bestatin and actinonin with cell-surface aminopeptidase inhibition in U937 and K562 cells. Their transporter-modifier experiments support a predominantly intracellular mechanism and show why verapamil-associated changes in drug sensitivity should not automatically be interpreted as evidence for calcium-signaling effects.
-
IMP and APEX-RNA-MS: Evidence Guide
2026-10-08
IMP is listed as SKU M1405, but the supplied dossier does not establish its chemical identity or mechanism. APEX-RNA-MS is a separate research strategy that profiles spatially proximal RNA modifications by combining proximity labeling with nucleoside LC-MS analysis.
-
Angiotensin II: From Vascular Signal to RAS Context
2026-10-07
Angiotensin II is more than a potent vasopressor: it is a context-dependent RAS signal linking receptor pharmacology, vascular remodeling, and ACE2 biology. This evidence-focused guide explains what current findings support, what remains uncertain, and how A1042 can be interpreted in research.
-
Ertugliflozin: Renal Transport to Brain Signaling
2026-10-07
Ertugliflozin (PF-04971729) is best known for glucose reabsorption inhibition, but emerging evidence links it to brain insulin signaling and tau biology. This article evaluates that kidney-to-brain hypothesis, explains the key rat-model findings, and defines the boundaries of current Alzheimer’s disease evidence.
-
UTP Solution and TRIM66: Five Evidence Questions
2026-10-06
A source-grounded overview of UTP biology, the TRIM66 olfactory-receptor study, evidence strength, interpretation, and the boundaries of what can reasonably be concluded.
-
2'-O-Methyladenosine: From Signal to Meaning
2026-10-06
2'-O-Methyladenosine is more than a modified nucleoside signal: it is a useful lens for separating analytical detection from biological interpretation. This article examines its RNA biology, purine metabolism context, research applications, and the evidence limits surrounding current UHPLC–MS/MS findings.
-
8-Oxo-GTP in Cell-Free Translation Research
2026-10-05
8-Oxo-GTP provides a useful lens for examining how altered guanine nucleotides may be interpreted in defined biochemical systems. This article connects that question to a 2025 study demonstrating continuous in situ synthesis of all 21 translation-relevant tRNAs in a recombinant PURE system, while clearly separating direct evidence from broader interpretation.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-10-05
The reference study identifies Kupffer cell-expressed TMEM16F as a central determinant of liver protection during Listeria monocytogenes infection. Its findings connect plasma-membrane repair and lipid scrambling with restrained inflammation, preserved hepatic metabolism, and reduced infection-associated tissue injury.
-
AAPH in Oxidative Stress Research: Evidence and Limits
2026-10-04
AAPH, or 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, is used conceptually as a water-soluble source of peroxyl-radical stress in biochemical and cellular research. Evidence from a 2024 hazelnut-protein study shows that AAPH-associated oxidation can alter solubility, interfacial properties, and gel structure, but the findings are model-specific and should not be treated as direct evidence of cellular, clinical, or food-storage outcomes.
-
APEX-RNA-MS Maps RNA Modifications in Cell Structures
2026-10-03
Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a proximity-labeling and nucleoside LC-MS strategy for measuring RNA modification patterns near defined protein neighborhoods. Applied to stress granules, P-bodies, and DNA damage foci, the study reports enrichment of m6A and m5C at DNA damage sites and identifies modified tRNA populations associated with stress granules.
-
NU7441 (KU-57788) DNA-PK Workflow Guide
2026-10-02
NU7441 (KU-57788) combines high DNA-PK selectivity with practical utility in DNA repair research, oncology research, and cell-cycle studies. This guide translates its biochemical profile and a brain pericyte HIV-1 study into assay-ready workflows, controls, and troubleshooting decisions.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-10-01
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for local treatment of bladder cancer. In cell and orthotopic mouse models, intravesical p21-LNP delivery restored nuclear p21, suppressed tumor growth, altered cell-cycle signaling, and limited systemic exposure, while remaining an experimental strategy rather than a clinical therapy.